Updated Jul 16, 2026 · Last SEC filing 2026-07-07
Cullinan Therapeutics, Inc. (CGEM) has filed 10 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-07. 5 Form 8-K material event filings were reported by CGEM in the last 90 days. 2 Form 144 notices of proposed sale were filed for CGEM stock. InsiderAlpha tracks every CGEM SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001789972 |
| Form 4 filings (90d) | 10 |
|---|---|
| Form 8-K filings (90d) | 5 |
| Form 144 notices (90d) | 2 |
| Latest Form 4 filing | 2026-07-07 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer | M — Option exercise | 4.0K | $4.30 | $17K | SEC | |
| Michaelson Jennifer | Chief Scientific Officer | S — Open-market sale | 8.0K | $17.82 | $143K | SEC | |
| SUMER JACQUELYN L | Chief Legal Officer | A — Grant or award | 2.5K | $8.60 | $21K | SEC | |
| Fenton Mary Kay | Chief Financial Officer | A — Grant or award | 1.5K | $8.60 | $13K | SEC | |
| Michaelson Jennifer | Chief Scientific Officer | S — Open-market sale | 7.8K | $14.60 | $114K | SEC | |
| Michaelson Jennifer | Chief Scientific Officer | S — Open-market sale | 200 | $15.58 | $3K | SEC | |
| Michaelson Jennifer | Chief Scientific Officer | M — Option exercise | 4.0K | $4.30 | $17K | SEC | |
| Michaelson Jennifer | Chief Scientific Officer | M — Option exercise [10b5-1] | 4.0K | $4.30 | $17K | SEC | |
| Michaelson Jennifer | Chief Scientific Officer | S — Open-market sale [10b5-1] | 8.0K | $15.68 | $125K | SEC | |
| Michaelson Jennifer | Chief Scientific Officer | S — Open-market sale [10b5-1] | 1.8K | $14.14 | $25K | SEC | |
| AHMED NADIM | President and CEO | S — Open-market sale | 13.5K | $14.47 | $196K | SEC | |
| SUMER JACQUELYN L | Chief Legal Officer | S — Open-market sale | 3.6K | $14.47 | $52K | SEC | |
| Michaelson Jennifer | Chief Scientific Officer | S — Open-market sale [10b5-1] | 3.6K | $14.47 | $52K | SEC | |
| Jones Jeffrey Alan | Chief Medical Officer | S — Open-market sale | 4.6K | $14.47 | $66K | SEC | |
| Michaelson Jennifer | Chief Scientific Officer | S — Open-market sale [10b5-1] | 1.8K | $13.99 | $25K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Cullinan Therapeutics, Inc. (CGEM). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Michaelson Jennifer | 7 | $294K |
| Allen Andrew R | 1 | — |
| Doyle Mittie | 1 | — |
| SUMER JACQUELYN L | 1 | $21K |
| Fenton Mary Kay | 1 | $13K |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in CGEM insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live CGEM dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.